The nature of these mutations can also be characterized by restriction fragment length polymorphisms (RFLP).
Mutations can also allow cancer cells to resist targeted cancer therapy.
Keratin mutations can also cause deformations in the hair, nails, and corneas.
These results underscore that distant mutations can also play role in optimizing efficiency via their contribution to the reorganization energy.
SCN1A mutations can also cause genetic epilepsy with febrile seizures plus (GEFS+), severe myoclonus epilepsy of infancy (SMEI) and some other rare epilepsy syndromes [57].
Driver mutations can also occur later in clonal evolution and infer resistant properties that were not present in the initial driver mutation.
Investigation and characterization of NSCLC mutations can also be used to identify biomarkers that can be used for early diagnosis and predicting patients' prognosis and response to treatment that can be used to determine a personalized therapeutic regimen.
Moreover, combined with targeted gene editing techniques (Liu et al., 2011b; Suzuki et al., 2014), iPSC-derived neural or skin cells free of pathogenic mutations can also be used for cell-replacement therapies via autologous transplantation.
And though the focus is understandably on BRCA mutations in women, these mutations can also be carried by men ― and potentially passed on to their children.
Whether LRRK2 mutations can also induce neuronal toxicity in vivo has not been demonstrated.
In addition, different OPA1 mutations can also result in variable energy defects [35], [36].
